ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: PP24 • ACR Convergence 2022

    Planting Seeds of Self-Advocacy: Increasing Healthcare Engagement in Children and Adolescents Through Arthritis Camp

    Kaye Anderson1, Kristine Carandang2 and Courtney Wells3, 1Young Patients' Autoimmune Research & Empowerment Alliance, River Falls, WI, 2Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA, 3University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN

    Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of ten. The constant battle between doctor appointments, pain, and medication side effects left…
  • Abstract Number: PP16 • ACR Convergence 2022

    Please Hear Me: How Effective Provider-Patient Communication Improved My Psoriatic Arthritis

    Ashley Krivohlavek, Oklahoma City, OK

    Background/Purpose: At age 12, I was diagnosed with psoriasis (PsO) followed by a diagnosis of psoriatic arthritis (PsA) at age 30. I'm now 38. In…
  • Abstract Number: 2189 • ACR Convergence 2022

    Impact of a Fatigue and Energy Management Program for Persons with Systemic Sclerosis (FAME-iSS): A Pilot Study

    Janet Poole1, Deirdre Connolly2, Jessica Salazar3 and Kristine Carandang4, 1University of New Mexico, Albuquerque, NM, 2School of Medicine, Trinity College, Dublin, Ireland, 3University of New Mexico, Occupational Therapy Graduate Program, Albuquerque, NM, 4Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA

    Background/Purpose: Fatigue is one of the most prevalent and disabling symptom reported by people with systemic sclerosis (SSc). No fatigue-specific programs exist for people with…
  • Abstract Number: 2251 • ACR Convergence 2022

    Reduction in Rheumatoid Arthritis-Associated Interstitial Lung Disease Risk in Patients Treated with Tofacitinib

    Matthew Baker1, Yuhan Liu1, Rong Lu1, Janice Lin1, Jason Melehani1 and William Robinson2, 1Stanford University, Stanford, CA, 2Stanford University School of Medicine, Palo Alto, CA

    Background/Purpose: Clinically significant interstitial lung disease (ILD) occurs in roughly 10% of patients with rheumatoid arthritis (RA). There are limited data on the pathogenesis of…
  • Abstract Number: PP21 • ACR Convergence 2022

    What Lies Beneath: Making Rheumatoid Arthritis Visible for the Seronegative Patient Through Blood Work

    Shilpa Venkatachalam, Global Healthy Living Foundation, New York, NY

    Background/Purpose: When I first received my Rheumatoid Arthritis (RA) diagnosis 5 years ago, I experienced a combination of relief and disbelief. Relief because now all…
  • Abstract Number: 2056 • ACR Convergence 2022

    Long Term Safety and Effectiveness of Belimumab Therapy in Patient with SLE: A Single Center Retrospective Analysis

    Takehiro Nakai1, Sho Fukui2, Takahiro Asano3, Futoshi Iwata4, Hiroki Ozawa5, Satoshi Kawaai4, Yukihiko Ikeda1, Hiromichi Tamaki1, Mitsumasa Kishimoto6, Kenichi YAMAGUCHI7 and Masato Okada1, 1St. Luke's International Hospital, Tokyo, Japan, 2Kyorin University Hospital, Tokyo, Japan, 3St. Luke's International Hospital, Chuo City Tokyo, Japan, 4St. Luke's International Hospital, Chuo-ku, Tokyo, Japan, 5Immuno-Rheumatology Center, St.Luke's International Hospital, Tokyo, Japan, 6Kyorin University School of Medicine, Yokohama, Japan, 7St.Luke's International Hospital, Tokyo, Japan

    Background/Purpose: Many clinicians use belimumab as a maintenance therapy of SLE, but there is scarce data on belimumab drug retention rate and safety/effectiveness profile in…
  • Abstract Number: 1621 • ACR Convergence 2022

    Genome-wide Association Study in African American Systemic Sclerosis Patients Identifies a Novel Target – Transforming Growth Factor-β3 (TGFβ3)

    Urvashi Kaundal1, Julia Hartman2, Emilee Stenson1, Sarah Safran1, Chloe Borden1, Mousumi Sahu1, Janet Wang1, Andrea Conte1, Ami Shah3, Maureen Mayes4, Ayo Doumatey5, Amy Bentley5, Daniel Shriner5, Robyn Domsic6, Thomas Medsger7, Paula Ramos8, Richard Silver8, Virginia Steen9, John Varga10, Vivien Hsu11, Lesley Ann Saketkoo12, Elena Schiopu13, Dinesh Khanna14, Jessica Gordon15, Lindsey Criswell16, Heather Gladue17, Chris Derk18, Elana Bernstein19, S. Louis Bridges, Jr.15, Victoria Shanmugam20, Lorinda Chung21, Suzanne Kafaja22, Reem Jan23, Marcin Trojanowski24, Avram Goldberg25, Benjamin Korman26, Settara Chandrasekharappa5, Yongbing Zhao27, Stephen Brooks27, Stefania Dell'Orso1, Adebowale Adeyemo5, Charles Rotimi5, Elaine Remmers5, Daniel Kastner5, Francesco Boin28, Rafael Casellas27, Fredrick Wigley29 and Pravitt Gourh30, 1National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, 2National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 3Johns Hopkins Rheumatology, Baltimore, MD, 4Division of Rheumatology and Clinical Immunogenetics, University of Texas McGovern Medical School, Houston, TX, 5National Human Genome Research Institute, Bethesda, MD, 6University of Pittsburgh, Pittsburgh, PA, 7University of Pittsburgh School of Medicine, Pittsburgh, PA, 8Medical University of South Carolina, Charleston, SC, 9Georgetown University School of Medicine, Washington, DC, 10University of Michigan, Ann Arbor, MI, 11Rutgers-RWJ Medical School, South Plainfield, NJ, 12University Medical Center - Comprehensive Pulmonary Hypertension Center and ILD Clinic Programs // New Orleans Scleroderma and Sarcoidosis Patient Care & Research Centeris, New Orleans, LA, 13Michigan Medicine, Ann Arbor, MI, 14Division of Rheumatology, Department of Internal Medicine, Scleroderma Program, University of Michigan, Ann Arbor, MI, 15Hospital for Special Surgery, New York, NY, 16National Human Genome Research Institute, NIH, Bethesda, MD, 17Arthritis & Osteoporosis Consultants of the Carolinas, Charlotte, NC, 18University of Pennsylvania, Philadelphia, PA, 19Columbia University, New York, NY, 20George Washington University, Great Falls, VA, 21Stanford University, Stanford, CA, 22UCLA Department of Medicine, Division of Rheumatology, Los Angeles, CA, 23University of Chicago, Chicago, IL, 24Boston University School of Medicine, Boston, MA, 25NYU Langone Medical Center - NYU Hospital for Joint Diseases, Lake Success, NY, 26University of Rochester, Rochester, NY, 27National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD, 28Cedars-Sinai Medical Center, Los Angeles, CA, 29Johns Hopkins University, Baltimore, MD, 30National Institutes of Health, Bethesda, MD

    Background/Purpose: Transforming Growth Factor-β (TGFβ) isoforms play an important role in extracellular matrix biology. Increased TGFβ-regulated gene signature has been observed in lesional skin and…
  • Abstract Number: 1623 • ACR Convergence 2022

    Combined Single-Cell, Bulk RNA Sequencing and Proteomics Analysis Reveals New Candidate Targets Involved in Myocardial Fibrogenesis

    Ievgeniia Kocherova1, Elena Pachera2, Daria Nurzynska3, Franca Di Meglio3, Oliver Distler4, Przemysław Błyszczuk2 and Gabriela Kania2, 1Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, 2Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, 3Department of Public Health, University of Naples "Federico II", Naples, Italy, 4Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland

    Background/Purpose: Inflammatory dilated cardiomyopathy (iDCM) often leads to heart failure (HF), which is the main cause of cardiac mortality in patients with systemic autoimmune diseases.…
  • Abstract Number: 2020 • ACR Convergence 2022

    Autophagy-related Risk Loci in Systemic Lupus Erythematous and Sjögren’s Disease

    Anna Nagel1, Bhuwan Khatri1, Marcin Radziszewski1, Mandi Wiley1, Anna Stolarczyk1, Michelle Joachims1, Kandice Tessneer1, Astrid Rasmussen1, Professor Simon Bowman2, Lida Radfar3, Roald Omdal4, Marie Wahren-Herlenius5, Blake Warner6, Torsten Witte7, Roland Jonsson8, Maureen Rischmueller9, Patrick Gaffney1, Judith James1, Lars Ronnblom10, Hal Scofield1, Xavier Mariette11, Marta Alarcon-Riquelme12, Fai Ng13, Gunnel Nordmark10, Qing Sun14, Kwangwoo Kim15, Sang-Cheol Bae16, Betty Tsao14, A. Darise Farris1 and Christopher Lessard1, 1Oklahoma Medical Research Foundation, Oklahoma City, OK, 2University Hospitals Birmingham, Birmingham, United Kingdom, 3University of Oklahoma Health Sciences Center, Oklahoma City, OK, 4Stavanger University, Stavanger, Norway, 5Karolinska Institutet, Stockholm, Sweden, 6National Institutes of Health, Bethesda, MD, 7MH-Hannover, Hannover, Germany, 8University of Bergen, Bergen, Norway, 9RheumatologySA, Adelaide, Australia, 10Uppsala University, Uppsala, Sweden, 11Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, 12Center for Genomics and Oncological Research (GENYO), Granada, Spain, 13Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom, 14Medical University of South Carolina, Charleston, SC, 15Kyung Hee University, Seoul, Republic of Korea, 16Hanyang University Medical Center, Seoul, Republic of Korea

    Background/Purpose: Dysregulated autophagy is implicated in systemic lupus erythematous (SLE) and Sjögren's disease (SjD), including dysregulated expression of Autophagy-related gene 5 (ATG5) and Autophagy Related…
  • Abstract Number: PP08 • ACR Convergence 2022

    Learning to Advocate for Myself and the Young Adult Community While Finding My Place as a Patient Partner at CARRA (Childhood Arthritis and Rheumatology Research Alliance)

    Ela Chintagunta1, Courtney Wells2 and Kristine Carandang3, 1Young Patients' Autoimmune Research & Empowerment Alliance, Chicago, IL, 2University of Wisconsin-River Falls; Young Patients' Autoimmune Research and Empowerment Alliance, St. Paul, MN, 3Young Patients' Autoimmune Research & Empowerment Alliance, San Diego, CA

    Background/Purpose: I was diagnosed with Juvenile Idiopathic Arthritis at the age of 13 when I was experiencing joint swelling in my lower body and my…
  • Abstract Number: PP17 • ACR Convergence 2022

    Engaging with the Spoon Theory: How I Make Decisions Using a Cost-Benefit Analysis That Works to Improve My Mental Health While Living with RA

    Stephanie Aleite, AiArthritis, St. Louis, MO

    Background/Purpose: Patients living with rheumatoid arthritis (RA) often also live with comorbid mental health conditions. Regardless of diagnosed mental health condition, living with a chronic…
  • Abstract Number: 2260 • ACR Convergence 2022

    Transcutaneous Vagal Nerve Stimulation Improves Destabilized Medial Meniscus-Induced Osteoarthritis Pain Associated with Significant Serum Biomarker Changes

    Shivmurat Yadav1, Monika Niewiadomska1, Lynsie Morris2, Taylor Conner2, Jessica Lumry2, Sanique South3, Emmaline Prinz2, Matlock Jeffries2, Timothy Griffin2, Stavros Stavrakis1 and Mary Beth Humphrey1, 1University of Oklahoma Health Sciences Center, Oklahoma City, OK, 2Oklahoma Medical Research Foundation, Oklahoma CIty, OK, 3Oklahoma Medical Research Foundation, Okahoma City, OK

    Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, affecting over 32.5 million US adults and characterized by pain, stiffness, swelling and functional disability.…
  • Abstract Number: 2199 • ACR Convergence 2022

    Primary Non-adherence to Biologics and Immunomodulatory Therapies for Rheumatoid Arthritis, Psoriatic Arthritis, and Spondyloarthritis Using Linked EHR and Pharmacy Claims Data

    Jeffrey Curtis1, Yujie Su2, Cassie Clinton2, Patrick Stewart3, Bryant England4, Tim Buekelman5 and Fenglong Xie2, 1Division of Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, 2University of Alabama at Birmingham, Birmingham, AL, 3Bendcare, Boca Raton, FL, 4University of Nebraska Medical Center, Omaha, NE, 5FASTER, Hoover, AL

    Background/Purpose: Many patients with autoimmune and inflammatory conditions discontinue biologics and other immunomodulatory medications prematurely, but many fail to even start (primary non-adherence). We examined…
  • Abstract Number: 2068 • ACR Convergence 2022

    All-Cause Mortality in a Systemic Lupus Erythematosus Cohort

    Michelle Petri1, Joseph Levy2, Urbano Sbarigia3 and Daniel W. Goldman1, 1Johns Hopkins University School of Medicine, Division of Rheumatology, Baltimore, MD, 2Bloomberg School of Public Health, Baltimore, MD, 3Johnson & Johnson, Beerse, Belgium

    Background/Purpose: Multiple studies have documented that patients with SLE have a higher all-cause mortality. Active disease contributes to early deaths with later deaths more likely…
  • Abstract Number: 2037 • ACR Convergence 2022

    Childhood-onset Sjögren’s Syndrome Is Characterised by Dysregulated of B and T Memory Cell Frequencies: A Pilot Immunophenotyping Analysis of This Rare Disease Phenotype

    Lucia Martin-Gutierrez1, Hannah Peckham2, Anna Radziszewska2, Junjie Peng2, Oluwatomisin Nettey2, Elizabeth Jury3 and Coziana Ciurtin4, 1Centre for Rheumatology Research, Department of Medicine,University College London, London, 2Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, 3University College London, London, United Kingdom, 4Centre for Adolescent Rheumatology Versus Arthritis, Department of Medicine, University College London, London, United Kingdom

    Background/Purpose: Sjögren's syndrome (SS) is an autoimmune rheumatic disease characterised by dryness resulting from chronic lymphocytic infiltration of the exocrine glands and extra glandular manifestations…
  • « Previous Page
  • 1
  • …
  • 436
  • 437
  • 438
  • 439
  • 440
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology